Expanding Our Target Discovery Collaboration with Boehringer Ingelheim into Cardiovascular Disease

Screenshot of write-up on Variant Bio’s expanded partnership in Fierce Biotech. Image credit: Fierce Biotech The best signal in a partnership is when both sides want to do more. Following on our $120mm deal with Boehringer Ingelheim (BI) on kidney disease earlier this year, we are thrilled to announce that after seeing the capabilities of our platform, BI has agreed to expand our existing collaboration into cardiovascular disease .